Assertio Agrees to Be Acquired by Garda Therapeutics
ASRT has more than doubled off its 52-week low of $7.706 on elevated volume (1.8× avg).
Summary
Assertio Holdings, Inc. has announced an agreement to be acquired by Garda Therapeutics. This is a highly material event for Assertio, as an acquisition fundamentally alters the company's future and investment thesis. While the headline does not provide specific financial terms or a premium, the definitive agreement signals a significant corporate transaction. This news will likely drive substantial trading activity and a re-evaluation of ASRT's stock price. Traders will be closely monitoring for the full terms of the deal, including the acquisition price and expected closing timeline.
At the time of this announcement, ASRT was trading at $18.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $118.7M. The 52-week trading range was $7.71 to $20.45. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.